Skip to main content
. 2018 Jul 16;37:153. doi: 10.1186/s13046-018-0810-7

Fig. 8.

Fig. 8

Working model of SAHA and Veliparib co-treatment. SAHA and veliparib exhibited synergistic anticancer efficacy in prostate cancer cells by two mechanisms: synergistically inducing DNA damage, and impairing DNA damage repair by reducing HR DNA repair molecule BRCA1 levels via UHRF1. Co-treatment promoted DNA damage and impaired the damaged DNA repair, and enhanced cell apoptosis and cell death